Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3878-3883

  Alffenaar, J W C ^a   Nienhuis, W A ^a   De Velde, F ^a   Zuur, A T ^a   Wessels, A M A ^a   Almeida, D ^b   Grosset, J ^b   Adjei, O ^c   Uges, D R A ^a   Van Der Werf, T S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCLARITHROMYCIN; CLARITHROMYCIN; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BURULI ULCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ULCERANS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANTIBIOTICS, ANTITUBERCULAR; BURULI ULCER; CHROMATOGRAPHY, LIQUID; CLARITHROMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMPIN; TANDEM MASS SPECTROMETRY;

EID: 77956109968     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00099-10     Document Type: Article

References (39)

1. Amsden, G. W. 2001. Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents 18(Suppl. 1):S11-S15.
2. Baciewicz, A. M., C. R. Chrisman, C. K. Finch, and T. H. Self. 2008. Update on rifampin and rifabutin drug interactions. Am. J. Med. Sci. 335:126-136.
3. Benedetti, M. S. 1995. Inducing properties of rifabutin and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol. Res. 32:177-187.
4. Bentoucha, A., J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 45:3109-3112.
5. Burkhardt, O., K. Borner, H. Stass, G. Beyer, M. Allewelt, C. E. Nord, and H. Lode. 2002. Single- and multiple-dose pharmacokinetics of oral moxi-floxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand. J. Infect. Dis. 34:898-903.
6. Carbon, C. 1995. Clinical relevance of intracellular and extracellular concentrations of macrolides. Infection 23(Suppl. 1):S10-S14.
7. Chen, J., and K. Raymond. 2006. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann. Clin. Microbiol. Antimicrob. 5:3.
8. Chu, S., Y. Park, C. Locke, D. S. Wilson, and J. C. Cavanaugh. 1992. Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. J. Clin. Pharmacol. 32:32-36.
9. Cole, S. T., and P. M. Alzari. 2005. Microbiology. TB - a new target, a new drug. Science 307:214-215.
10. Coutanceau, E., L. Marsollier, R. Brosch, E. Perret, P. Goossens, M. Tanguy, S. T. Cole, P. L. Small, and C. Demangel. 2005. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell. Microbiol. 7:1187-1196.
11. Dega, H., A. Bentoucha, J. Robert, V. Jarlier, and J. Grosset. 2002. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 46:3193-3196.
12. Dega, H., J. Robert, P. Bonnafous, V. Jarlier, and J. Grosset. 2000. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 44:2367-2372.
13. de Velde, F., J. W. Alffenaar, A. M. Wessels, B. Greijdanus, and D. R. Uges. 2009. Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877:1771-1777.
14. Eberl, S., B. Renner, A. Neubert, M. Reisig, I. Bachmakov, J. Konig, F. Dorje, T. E. Murdter, A. Ackermann, H. Dormann, K. G. Gassmann, E. G. Hahn, S. Zierhut, K. Brune, and M. F. Fromm. 2007. Role of P-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin. Pharmacokinet. 46:1039-1049.
15. Etuaful, S., B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, G. K. Amedofu, P. Awuah, E. Ampadu, G. Amofah, K. Asiedu, and M. Wansbrough-Jones. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 49:3182-3186.
16. George, K. M., D. Chatterjee, G. Gunawardana, D. Welty, J. Hayman, R. Lee, and P. L. Small. 1999. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283:854-857.
17. Guay, D. R., L. E. Gustavson, K. J. Devcich, J. Zhang, G. Cao, and C. A. Olson. 2001. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin. Ther. 23:566-577.
18. Gurley, B., M. A. Hubbard, D. K. Williams, J. Thaden, Y. Tong, W. B. Gentry, P. Breen, D. J. Carrier, and S. Cheboyina. 2006. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J. Clin. Pharmacol. 46:201-213.
19. Hafner, R., J. Bethel, M. Power, B. Landry, M. Banach, L. Mole, H. C. Standiford, S. Follansbee, P. Kumar, R. Raasch, D. Cohn, D. Mushatt, and G. Drusano. 1998. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob. Agents Chemother. 42:631-639.
20. Hayman, J. 1993. Out of Africa: observations on the histopathology of Mycobacterium ulcerans infection. J. Clin. Pathol. 46:5-9.
21. Herbinger, K. H., O. Adjei, N. Y. wua-Boateng, W. A. Nienhuis, L. Kunaa, V. Siegmund, J. Nitschke, W. Thompson, E. Klutse, P. Agbenorku, A. Schipf, S. Reu, P. Racz, B. Fleischer, M. Beissner, E. Fleischmann, K. Helfrich, T. S. van der Werf, T. Loscher, and G. Bretzel. 2009. Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin. Infect. Dis. 48:1055-1064.
22. Holdiness, M. R. 1984. Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet. 9:511-544.
23. Jayaram, R., S. Gaonkar, P. Kaur, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharat, R. K. Shandil, E. Kantharaj, and V. Balasubramanian. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob. Agents Chemother. 47:2118-2124.
24. Ji, B., A. Chauffour, J. Robert, S. Lefrancois, and V. Jarlier. 2007. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 51:3737-3739.
25. Marsollier, L., N. Honore, P. Legras, A. L. Manceau, H. Kouakou, B. Carbonnelle, and S. T. Cole. 2003. Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob. Agents Chemother. 47:1228-1232.
26. Nienhuis, W. A., Y. Stienstra, W. A. Thompson, P. C. Awuah, K. M. Abass, W. Tuah, N. Y. Awua-Boateng, E. O. Ampadu, V. Siegmund, J. P. Schouten, O. Adjei, G. Bretzel, and T. S. van der Werf. 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375:664-672.
27. Oliveira, M. S., A. G. Fraga, E. Torrado, A. G. Castro, J. P. Pereira, A. L. Filho, F. Milanezi, F. C. Schmitt, W. M. Meyers, F. Portaels, M. T. Silva, and J. Pedrosa. 2005. Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect. Immun. 73:6299-6310.
28. Peloquin, C. A., and S. E. Berning. 1997. Evaluation of the drug interaction between clarithromycin and rifampin. J. Infect. Dis. Pharmacother. 2:19-35.
29. Peloquin, C. A., R. Namdar, M. D. Singleton, and D. E. Nix. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
30. Portaels, F., H. Traore, K. De Ridder, and W. M. Meyers. 1998. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob. Agents Chemother. 42:2070-2073.
31. Proost, J. H., and D. K. Meijer. 1992. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput. Biol. Med. 22:155-163.
32. Rodvold, K. A. 1999. Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokinet. 37:385-398.
33. Stinear, T. P., M. J. Pryor, J. L. Porter, and S. T. Cole. 2005. Functional analysis and annotation of the virulence plasmid pMUM001 from Mycobacterium ulcerans. Microbiology 151:683-692.
34. Torrado, E., A. G. Fraga, A. G. Castro, P. Stragier, W. M. Meyers, F. Portaels, M. T. Silva, and J. Pedrosa. 2007. Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect. Immun. 75:977-987.
35. Traunmuller, F., M. Zeitlinger, P. Zeleny, M. Muller, and C. Joukhadar. 2007. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antimicrob. Agents Chemother. 51:3185-3189.
36. van der Werf, T. S., T. Stinear, Y. Stienstra, W. T. van der Graaf, and P. L. Small. 2003. Mycolactones and Mycobacterium ulcerans disease. Lancet 362:1062-1064.
37. Wallace, R. J., Jr., B. A. Brown, D. E. Griffith, W. Girard, and K. Tanaka. 1995. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J. Infect. Dis. 171:747-750.
38. Williamson, H. R., M. E. Benbow, K. D. Nguyen, D. C. Beachboard, R. K. Kimbirauskas, M. D. McIntosh, C. Quaye, E. O. Ampadu, D. Boakye, R. W. Merritt, and P. L. Small. 2008. Distribution of Mycobacterium ulcerans in Buruli ulcer endemic and non-endemic aquatic sites in Ghana. PLoS Negl. Trop. Dis. 2:e205.
39. Zent, C., and P. Smith. 1995. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber. Lung Dis. 76:109-113.